9p21.3 coronary artery disease risk variants disrupt TEAD transcription factor-dependent transforming growth factor β regulation of p16 expression in human aortic smooth muscle cells

Circulation

Volumn 132, Issue 21, 2015, Pages 1969-1978

  Almontashiri, Naif A M ^a,b,c   Antoine, Darlène ^a,b   Zhou, Xun ^d   Vilmundarson, Ragnar O ^a,b   Zhang, Sean X ^a   Hao, Kennedy N ^a   Chen, Hsiao Huei ^d,e   Stewart, Alexandre F R ^a,b,e  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c TAIBAH UNIVERSITY   (Saudi Arabia)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

atherosclerosis; coronary disease; genetics; molecular biology; smooth muscle cells

Indexed keywords

PROTEIN P15; PROTEIN P16; STAT1 PROTEIN; TEAD TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA BINDING PROTEIN; MUSCLE PROTEIN; RECOMBINANT PROTEIN; TEAD3 PROTEIN, HUMAN; TEAD4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ALLELE; ANTIGEN BINDING; ARTICLE; BINDING SITE; CELL AGING; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME; CHROMOSOME 9P21.3; COMPLEX FORMATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DNA FLANKING REGION; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR SMOOTH MUSCLE CELL; ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; AORTA; BIOSYNTHESIS; CELL CULTURE; CHROMOSOME 9; CYTOLOGY; GENE SILENCING; GENETICS; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REPORTER GENE; TUMOR SUPPRESSOR GENE; VASCULAR SMOOTH MUSCLE; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; AORTA; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 9; CORONARY DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENES, P16; GENES, REPORTER; HUMANS; MALE; MIDDLE AGED; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84948079490     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.015023     Document Type: Article

References (53)

1. Nabel EG, Braunwald E A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012; 366: 54-63. doi: 10.1056/NEJMra1112570.
2. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007; 316: 1491-1493. doi: 10.1126/science.1142842.
3. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC A common allele on chromosome 9 associated with coronary heart disease. Science. 2007; 316: 1488-1491. doi: 10.1126/.science.1142447.
4. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, König IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H. WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007; 357: 443-453. doi: 10.1056/.NEJMoa072366.
5. WTCCC. Genome-wide association study of. 14, 000 cases of seven common diseases and. 3, 000 shared controls. Nature. 2007; 447: 661-78.
6. Dandona S, Chen L, Fan M, Alam MA, Assogba O, Belanger M, Williams K, Wells GA, Tang WH, Ellis SG, Hazen SL, McPherson R, Roberts R, Stewart AF. The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Hum Genet. 2010; 127: 101-105. doi: 10.1007/s00439-009-0761-3.
7. Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J, Helgadottir A, Holm H, Gulcher JR, Stefansson K, Waddy S, Vaccarino V, Zafari AM, Quyyumi AA. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J. 2010; 31: 3017-3023. doi: 10.1093/eurheartj/ehq272.
8. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, Jääskeläinen JE, Kyo Y, Lenk GM, Sakalihasan N, Kostulas K, Gottsäter A, Flex A, Stefansson H, Hansen T, Andersen G, Weinsheimer S, Borch-Johnsen K, Jorgensen T, Shah SH, Quyyumi AA, Granger CB, Reilly MP, Austin H, Levey AI, Vaccarino V, Palsdottir E, Walters GB, Jonsdottir T, Snorradottir S, Magnusdottir D, Gudmundsson G, Ferrell RE, Sveinbjornsdottir S, Hernesniemi J, Niemelä M, Limet R, Andersen K, Sigurdsson G, Benediktsson R, Verhoeven EL, Teijink JA, Grobbee DE, Rader DJ, Collier DA, Pedersen O, Pola R, Hillert J, Lindblad B, Valdimarsson EM, Magnadottir HB, Wijmenga C, Tromp G, Baas AF, Ruigrok YM, van Rij AM, Kuivaniemi H, Powell JT, Matthiasson SE, Gulcher JR, Thorgeirsson G, Kong A, Thorsteinsdottir U, Stefansson K. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 008; 40: 217-224. doi: 10.1038/ng.72.
9. Zollbrecht C, Grassl M, Fenk S, Höcherl R, Hubauer U, Reinhard W, Esslinger UB, Ebert S, Langmann T, Stark K, Hengstenberg C. Expression pattern in human macrophages dependent on 9p213 coronary artery disease risk locus. Atherosclerosis. 2013; 227: 244-249. doi: 10.1016/j. atherosclerosis.2012.12.030.
10. Loinard C, Basatemur G, Masters L, Baker L, Harrison J, Figg N, Vilar J, Sage AP, Mallat Z. Deletion of chromosome 9p21 noncoding cardiovascular risk interval in mice alters Smad2 signaling and promotes vascular aneurysm. Circ Cardiovasc Genet. 2014; 7: 799-805. doi: 10.1161/.CIRCGENETICS.114.000696.
11. Motterle A, Pu X, Wood H, Xiao Q, Gor S, Ng FL, Chan K, Cross F, Shohreh B, Poston RN, Tucker AT, Caulfield MJ, Ye S. Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet. 2012; 21: 4021-4029. doi: 10.1093/hmg/dds224.
12. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM, Pennacchio LA. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010; 464: 409-412. doi: 10.1038/nature08801.
13. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2012; 130: 1715-1725. doi: 10.1002/.ijc.27316.
14. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004; 114: 1299-1307. doi: 10.1172/JCI22475.
15. Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014; 129: 1551-1559. doi: 10.1161/CIRCULATIONAHA.113.005015.
16. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011; 8: 92-102. doi: 10.1038/nrcardio.2010.180.
17. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, Buerki C, McLean BW, Cook RC, Parker JS, McPherson R. Functional analysis of the chromosome 9p213 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol. 2009; 29: 1671-1677. doi: 10.1161/.ATVBAHA.109.189522.
18. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu XD, Topol EJ, Rosenfeld MG, Frazer KA. 9p21 DNA variants associated with coronary artery disease impair interferon-? signalling response. Nature. 2011; 470: 264-268. doi: 10.1038/nature09753.
19. Almontashiri NA, Fan M, Cheng BL, Chen HH, Roberts R, Stewart AF. Interferon-? activates expression of p15 and p16 regardless of 9p213 coronary artery disease risk genotype. J Am Coll Cardiol. 2013; 61: 143-147. doi: 10.1016/j.jacc.2012.08.1020.
20. Musunuru K. Enduring mystery of the chromosome 9p213 locus. Circ Cardiovasc Genet. 2013; 6: 224-225. doi: 10.1161/.CIRCGENETICS.113.000132.
21. Stewart AF, Richard CW 3rd, Suzow J, Stephan D, Weremowicz S, Morton CC, Adra CN. Cloning of human RTEF-1, a transcriptional enhancer factor-1-related gene preferentially expressed in skeletal muscle: evidence for an ancient multigene family. Genomics. 1996; 37: 68-76.
22. Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-Adrenergic activation of gene expression in cardiac myocytes. J Biol Chem. 2004; 279: 30800-30806. doi: 10.1074/jbc.M400154200.
23. Mahoney WM Jr, Hong JH, Yaffe MB, Farrance IK. The transcriptional co-Activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J. 2005; 388(Pt 1): 217-225. doi: 10.1042/BJ20041434.
24. Maeda T, Chapman DL, Stewart AF. Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. J Biol Chem. 2002; 277: 48889-48898. doi: 10.1074/jbc. M206858200.
25. Benhaddou A, Keime C, Ye T, Morlon A, Michel I, Jost B, Mengus G, Davidson I. Transcription factor TEAD4 regulates expression of myogenin and the unfolded protein response genes during C2C12 cell differentiation. Cell Death Differ. 2012; 19: 220-231. doi: 10.1038/cdd.2011.87.
26. Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev. 2008; 22: 3320-3334. doi: 10.1101/gad.1726608.
27. Vijayachandra K, Higgins W, Lee J, Glick A. Induction of p16ink4a and p19ARF by TGFbeta1 contributes to growth arrest and senescence response in mouse keratinocytes. Mol Carcinog. 2009; 48: 181-186. doi: 10.1002/mc.20472.
28. Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, Hida T, Tsujimura T, Osada H, Sekido Y. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012; 209: 479-494. doi: 10.1084/jem.20111653.
29. Gan Q, Yoshida T, Li J, Owens GK. Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-Actin expression. Circ Res. 2007; 101: 883-892. doi: 10.1161/.CIRCRESAHA.107.154831.
30. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem. 2003; 278: 13008-13015. doi: 10.1074/jbc.M210366200.
31. Farrance IK, Mar JH, Ordahl CP. M-CAT binding factor is related to the SV40 enhancer binding factor, TEF-1. J Biol Chem. 1992; 267: 17234-17240.
32. Maeda T, Maeda M, Stewart AF. TEF-1 transcription factors regulate activity of the mouse mammary tumor virus LTR. Biochem Biophys Res Commun. 2002; 296: 1279-1285.
33. Stewart AF, Suzow J, Kubota T, Ueyama T, Chen HH. Transcription factor RTEF-1 mediates alpha1-Adrenergic reactivation of the fetal gene program in cardiac myocytes. Circ Res. 1998; 83: 43-49.
34. Hellman LM, Fried MG. Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nat Protoc. 2007; 2: 1849-1861. doi: 10.1038/nprot.2007.249.
35. Chen Z, Friedrich GA, Soriano P. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Dev. 1994; 8: 2293-2301.
36. Milewski RC, Chi NC, Li J, Brown C, Lu MM, Epstein JA. Identification of minimal enhancer elements sufficient for Pax3 expression in neural crest and implication of Tead2 as a regulator of Pax3. Development. 2004; 131: 829-837. doi: 10.1242/dev.00975.
37. Hannon GJ, Beach D. p15INK4B is a potential effector of TGFbeta-induced cell cycle arrest. Nature. 1994; 371: 257-261. doi: 10.1038/371257a0.
38. Reynisdóttir I, Polyak K, Iavarone A, Massagué J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995; 9: 1831-1845.
39. Zheng Y, Devitt C, Liu J, Mei J, Skapek SX A distant, cis-Acting enhancer drives induction of Arf by Tgfβ in the developing eye. Dev Biol. 2013; 380: 49-57. doi: 10.1016/j.ydbio.2013.05.003.
40. MacLellan WR, Lee TC, Schwartz RJ, Schneider MD. Transforming growth factor-beta response elements of the skeletal alpha-Actin gene. Combinatorial action of serum response factor, YY1, and the SV40 enhancer-binding protein, TEF-1. J Biol Chem. 1994; 269: 16754-16760.
41. Liu F, Wang X, Hu G, Wang Y, Zhou J. The transcription factor TEAD1 represses smooth muscle-specific gene expression by abolishing myocardin function. J Biol Chem. 2014; 289: 3308-3316.
42. Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, Kuivaniemi H. Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics. 2007; 8: 237. doi: 10.1186/1471-2164-8-237.
43. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev. 2001; 81: 999-1030.
44. Reifenberg K, Cheng F, Orning C, Crain J, Kper I, Wiese E, Protschka M, Blessing M, Lackner KJ, Torzewski M. Overexpression of TGF1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice. PLoS One. 2012; 7: e40990. doi: 10.1371/journal. pone.0040990.
45. Borkowski P, Robinson MJ, Kusiak JW, Borkowski A, Brathwaite C, Mergner WJ. Studies on TGF-beta 1 gene expression in the intima of the human aorta in regions with high and low probability of developing atherosclerotic lesions. Mod Pathol. 1995; 8: 478-482.
46. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999; 104: 1191-1197. doi: 10.1172/JCI7709.
47. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010; 120: 422-432. doi: 10.1172/.JCI38136.
48. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest. 1992; 90: 456-461. doi: 10.1172/JCI115881.
49. Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2013; 14: 390-398. doi: 10.4161/cbt.23788.
50. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 2001; 413: 86-91. doi: 10.1038/35092592.
51. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest. 2005; 115: 3228-3238. doi: 10.1172/JCI22756.
52. Chen HH, Almontashiri NA, Antoine D, Stewart AF. Functional genomics of the 9p213 locus for atherosclerosis: clarity or confusion? Curr Cardiol Rep. 2014; 16: 502. doi: 10.1007/s11886-014-0502-7.
53. Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, Wang X, Guo T, Li P, Zhao Y, Ji H, Zhang L, Zhou Z A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014; 25: 166-180. doi: 10.1016/j. ccr.2014.01.010.